EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Three-dimensional bioprinted organoids: advances and clinical translation

Yi Zhang, Zhen Huang, Beichen Wang, Bing Li, Yunfeng Yang

Regenerative Biomaterials · 22.01.2026 · 13

DOI: 10.1093/rb/rbag142 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Regenerative Biomaterials, online erschienen am 30.06.2026. Verfasst von Yi Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200092, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, Shanghai Committee of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Three-dimensional (3D) bioprinting enables the precise fabrication of complex tissue constructs by depositing living cells, biomaterials, and bioactive factors in a spatially controlled manner. Concurrently, organoids—self-organizing 3D cellular structures that recapitulate key aspects of organ architecture and function—have revolutionized biomedical research by providing physiologically relevant models for disease modeling, drug screening, and regenerative medicine. The convergence of 3D bioprinting and organoid technology represents a significant advancement, offering new opportunities for personalized medicine and tissue engineering. This review examines the current state of 3D bioprinted organoids, encompassing bioprinting techniques, bio-ink development, and diverse clinical applications spanning oncology (patient-derived tumor organoids for predicting therapy response in selected gastrointestinal cancers), regenerative medicine (bioprinted bone, cartilage, cardiac, and skin constructs), drug discovery (hepatotoxicity and nephrotoxicity screening platforms), and personalized therapeutics. We discuss technological advances supporting translational development, while distinguishing clinically validated patient-derived tumor organoid evidence from preclinical and proof-of-concept regenerative applications, and critically analyze the challenges that must be addressed for widespread clinical adoption. Finally, we provide perspectives on future directions, including the integration of artificial intelligence, multiorganoid systems, and regulatory pathways that will shape the next generation of 3D bioprinted organoids for clinical use.

Schlagwörter

Stichwörter der Autor:innen

3D bioprintingbio-inksclinical translationorganoidspersonalized medicineregenerative medicinetissue engineering

Autor:innen und Institutionen

  • Department of Orthopedics, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200092, China.
  • Department of Orthopedics, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China.
  • Department of Orthopedics, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou 350212, China.
  • Department of Orthopedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

Förderung

  • National Key R&D Program of China
  • Shanghai Committee of Science and Technology

Zitieren

APA

Zhang, Y., Huang, Z., Wang, B., Li, B., & Yang, Y. (2026). Three-dimensional bioprinted organoids: advances and clinical translation. Regenerative Biomaterials, 13. https://doi.org/10.1093/rb/rbag142

Vancouver

Zhang Y, Huang Z, Wang B, Li B, Yang Y. Three-dimensional bioprinted organoids: advances and clinical translation. Regenerative Biomaterials. 2026;13. doi:10.1093/rb/rbag142

BibTeX
@article{Zhang2026,
  author = {Zhang, Yi and Huang, Zhen and Wang, Beichen and Li, Bing and Yang, Yunfeng},
  title = {Three-dimensional bioprinted organoids: advances and clinical translation},
  journal = {Regenerative Biomaterials},
  year = {2026},
  volume = {13},
  doi = {10.1093/rb/rbag142}
}
Kostenlos starten →